中国临床药理学杂志2016，Vol.32Issue(6)：492-494,3.DOI:10.13699/j.cnki.1001-6821.2016.06.004
苦碟子联合坎地沙坦治疗2型糖尿病肾病的临床疗效及安全性
Clinical efficacy and safety of Kudiezi combined with candesartan in the treatment of type 2 diabetic nephropathy
摘要
Abstract
Objective To evaluate the clinical efficacy and safety of Kudiezi and candesartan in patients with type 2 diabetic nephropathy.Methods A total of 358 patients with type 2 diabetic nephropathy were randomly divided into treatment group and control group, 179 cases in each group.Control group was treated with candesartan 8 mg, while the treatment group given Kudiezi injection 40 mL on the basis of control group, all patients were treated for a month.Clinical efficiency and se-rum stem cell factor ( HGF ) , transforming growth factor ( TGF -β1 ) , cystatin C( Cys C) , glucose and glycated hemoglobin levels, mean arteri-al pressure and renal function and adverse reactions were observed in the two groups before and after treatment.Results Total effective rate in treatment group was 91.62%, significantly higher than 77.10% in con-trol group (P<0.05).The HGF, CysC, TGF-β1 in treatment group were significantly better than those in control group ( P <0.05 ).After treatment, the serum creatinine, blood urea nitrogen, β2 -microglobu-lin, urinary albumin excretion rate in treatment group were significantly better than those of control group ( P <0.05 ).The incidence rate of adverse drug reactions had no significant difference in two groups ( P>0.05).Conclusion For the treatment of type 2 diabetic nephropathy, the combined therapy of Kudiezi and candesartan can improve patients’ HGF, TGF-β1 , Cys C levels and kidney func-tion, the effect is obvious with high safety.关键词
苦碟子注射液/坎地沙坦/2型糖尿病肾病/肾功能Key words
Kudiezi/candesartan/type 2 diabetic nephropathy/kidney function分类
医药卫生引用本文复制引用
金菊庆,张挺..苦碟子联合坎地沙坦治疗2型糖尿病肾病的临床疗效及安全性[J].中国临床药理学杂志,2016,32(6):492-494,3.基金项目
2013年义乌市科研计划基金资助项目 （）
